Corcept's Hypercortisolism Sales Outlook Seen as Unrealistic -- Market Talk

Dow Jones12-17

1454 ET - Corcept Therapeutics isn't likely to see the sales numbers it wants from its hypercortisolism treatments, UBS analysts wrote in a note. For Korlym, Corcept's existing hypercortisolism product, and relacorilant, which is awaiting FDA approval, they forecast sales for hypercortisolism patients of roughly $1.4 billion through 2030, well below the company's outlook of $3 billion to $5 billion. To hit that goal, Corcept would need to scale its distribution capacity and see persistent physician behavior changes and near-total Korlym-to-relacorilant conversion with rapid uptake -- an outcome they said was unlikely. Shares are down 9.5% to $79.01. (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

December 16, 2025 14:55 ET (19:55 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592932836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 03:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592932836","market":"hk","top_or_hot":-1,"title":"Corcept's Hypercortisolism Sales Outlook Seen as Unrealistic -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1454 ET - Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> isn't likely to see the sales numbers it wants from its hypercortisolism treatments, UBS analysts wrote in a note. For Korlym, Corcept's existing hypercortisolism product, and relacorilant, which is awaiting FDA approval, they forecast sales for hypercortisolism patients of roughly $1.4 billion through 2030, well below the company's outlook of $3 billion to $5 billion. To hit that goal, Corcept would need to scale its distribution capacity and see persistent physician behavior changes and near-total Korlym-to-relacorilant conversion with rapid uptake -- an outcome they said was unlikely. Shares are down 9.5% to $79.01. (elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 14:55 ET (19:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept's Hypercortisolism Sales Outlook Seen as Unrealistic -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept's Hypercortisolism Sales Outlook Seen as Unrealistic -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-17 03:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1454 ET - Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> isn't likely to see the sales numbers it wants from its hypercortisolism treatments, UBS analysts wrote in a note. For Korlym, Corcept's existing hypercortisolism product, and relacorilant, which is awaiting FDA approval, they forecast sales for hypercortisolism patients of roughly $1.4 billion through 2030, well below the company's outlook of $3 billion to $5 billion. To hit that goal, Corcept would need to scale its distribution capacity and see persistent physician behavior changes and near-total Korlym-to-relacorilant conversion with rapid uptake -- an outcome they said was unlikely. Shares are down 9.5% to $79.01. (elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 14:55 ET (19:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592932836","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592932836","pubTimestamp":1765914900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1454 ET - Corcept Therapeutics isn't likely to see the sales numbers it wants from its hypercortisolism treatments, UBS analysts wrote in a note. For Korlym, Corcept's existing hypercortisolism product, and relacorilant, which is awaiting FDA approval, they forecast sales for hypercortisolism patients of roughly $1.4 billion through 2030, well below the company's outlook of $3 billion to $5 billion. To hit that goal, Corcept would need to scale its distribution capacity and see persistent physician behavior changes and near-total Korlym-to-relacorilant conversion with rapid uptake -- an outcome they said was unlikely. Shares are down 9.5% to $79.01. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0566484027.USD":"安本美国小盘成长股","BK4532":"文艺复兴科技持仓","CORT":"Corcept医疗","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H"},"translate_title":"Corcept的皮质醇增多症销售前景被认为不切实际——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":0.9},"content_text":"1454 ET - Corcept Therapeutics isn't likely to see the sales numbers it wants from its hypercortisolism treatments, UBS analysts wrote in a note. For Korlym, Corcept's existing hypercortisolism product, and relacorilant, which is awaiting FDA approval, they forecast sales for hypercortisolism patients of roughly $1.4 billion through 2030, well below the company's outlook of $3 billion to $5 billion. To hit that goal, Corcept would need to scale its distribution capacity and see persistent physician behavior changes and near-total Korlym-to-relacorilant conversion with rapid uptake -- an outcome they said was unlikely. Shares are down 9.5% to $79.01. (elias.schisgall@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 14:55 ET (19:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592932836","isCrawlerRequest":true}